Structure of MSA-2
CAS No.: 129425-81-6
*Storage:
*Shipping:
MSA-2 is a STING agonist with anti-tumor activity that may be used in combination with anti-PD-1 therapy.
Synonyms: 5,6-dimethoxy-γ-oxo-benzo[b]thiophene-2-Butanoic Acid
4.5
*For Research Use Only !
Change View
Size | Price | US Stock | Global Stock | In Stock |
25mg | łËÇ˶ÊÊ | Inquiry | Inquiry | |
50mg | ł§ÿî¶ÊÊ | Inquiry | Inquiry | |
100mg | łÿóǶÊÊ | Inquiry | Inquiry | |
250mg | łÇʧď¶ÊÊ | Inquiry | Inquiry | |
1g | łËÿîʶÊÊ | Inquiry | Inquiry |
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
łËÇ˶ÊÊ
ł§ÿî¶ÊÊ
łÿóǶÊÊ
łÇʧď¶ÊÊ
łËÿîʶÊÊ
In Stock
- +
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 129425-81-6 |
Formula : | C14H14O5S |
M.W : | 294.32 |
SMILES Code : | O=C(O)CCC(C1=CC2=CC(OC)=C(OC)C=C2S1)=O |
Synonyms : |
5,6-dimethoxy-γ-oxo-benzo[b]thiophene-2-Butanoic Acid
|
MDL No. : | MFCD32640674 |
InChI Key : | APCLRHPWFCQIMG-UHFFFAOYSA-N |
Pubchem ID : | 23035251 |
GHS Pictogram: | ![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501 |
In Vitro:
Cell Line
| Concentration | Treated Time | Description | References |
Bone marrow-derived macrophages (BMDM) | 0.01 mg/ml | 1 day | To assess the effect of MSA-2 on macrophage polarization, results showed MSA-2 significantly increased M1-like markers (CD86, H-2Kd) and proinflammatory cytokines (IFN-β, IL-6, TNF-α). | PMC9548169 |
Bone marrow-derived dendritic cells (BMDC) | 0.01 mg/ml | 1 day | To evaluate the effect of MSA-2 on STING pathway activation, results showed MSA-2 significantly upregulated DC maturation markers (CD80, CD86, H-2Kd, I-A/I-E) and proinflammatory cytokines (IFN-β, IL-6, TNF-α). | PMC9548169 |
THP-1 cells | 20 μM | 1 hour | Evaluate the activation effect of MSA-2 on the cGAS/STING signaling pathway in THP-1 cells | PMC10916235 |
D2.0R cells | 10-50 μM | 16-48 hours | To evaluate the effect of MSA-2 on NK cell killing of D2.0R cells, results showed MSA-2 significantly enhanced NK cell killing | PMC11474167 |
Short-term expanded Vδ2 γδ T-cell lines | 25 µM | 24 h | MSA-2 co-stimulated cytokine induction but induced cell death | PMC8812774 |
Monocytes | 25 µM | 24 h | MSA-2 stimulated IL-1β and TNF-α secretion and induced cell death | PMC8812774 |
Vδ2 T cells | 25 µM | 24 h | MSA-2 co-stimulated cytokine induction but inhibited proliferation | PMC8812774 |
THP1 cells | 40 μM | 24 hours | To validate STING activation by SAProsome-3 in THP1 cells, results showed upregulation of IFN-β, TNF-α, and CXCL10 mRNA expression and activation of STING downstream signaling. | PMC10390568 |
Bone marrow-derived dendritic cells (BMDC) | 40 μM | 24 hours | To evaluate the STING pathway activation by SAProsomes, results showed significant upregulation of IFN-β, TNF-α, and CXCL10 mRNA expression and promotion of DC maturation. | PMC10390568 |
STING knockout PK-15 cells | 30 μM | 24 hours | To verify whether the antiviral effect of MSA-2 depends on STING, results showed MSA-2 failed to inhibit SVV replication in STING knockout cells. | PMC10675287 |
PK-15 cells | 30 μM | 24 hours | To evaluate the inhibitory effect of MSA-2 on SVV replication, results showed MSA-2 significantly reduced viral RNA levels and virus titers. | PMC10675287 |
RAW264.7 cells | 10, 50 μM | 24 hours | Evaluate the effect of MSA-2 and MSA-2-Pt on the secretion of IFN-β by RAW264.7 cells. The results showed that both could trigger the secretion of IFN-β. | PMC10795137 |
MC38 cells | 25, 50, 75, 100, 200, 300 μM | 24 hours | Evaluate the effect of MSA-2 and MSA-2-Pt on the viability of MC38 cells. The results showed that MSA-2-Pt induced cell death significantly from 75 μM, showing a dose-dependent response, while MSA-2 did not cause cell death until 300 μM. | PMC10795137 |
RAW264.7 cells | 10, 25, 50 μM | 3 hours | Evaluate the activation of the STING signaling pathway by MSA-2 and MSA-2-Pt. The results showed that both MSA-2-Pt and MSA-2 increased the levels of phosphorylated P65 (P-P65). | PMC10795137 |
Mouse bone marrow-derived dendritic cells | 10 µM MSA-2 | 30 min pretreatment followed by 2h exposure to LLC-conditioned media | To assess the effect of STING agonist MSA-2 on Ch25h mRNA expression, results showed MSA-2 partially prevented tumor-conditioned media-induced downregulation of Ch25h mRNA | PMC9636202 |
MCF7 cells | 35 μM | 6 hours | To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance. | PMC11828882 |
A549 cells | 35 μM | 6 hours | To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance. | PMC11828882 |
CT26 cells | 35 μM | 6 hours | To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance. | PMC11828882 |
B16F10 cells | 35 μM | 6 hours | To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance. | PMC11828882 |
In Vivo:
Species
| Animal Model
| Administration | Dosage | Frequency | Description | References |
BALB/c mice | Metastatic dormancy model of breast cancer | Intraperitoneal injection | 1 mg per dose | Single dose, 7 days post-inoculation | To evaluate the effect of MSA-2 on breast cancer metastatic dormancy, results showed a single dose significantly prolonged mouse survival time | PMC11474167 |
Mice | Bilateral 4T1 tumor-bearing mice model | Intravenous injection | 10 mg/kg | Single injection, observed for 21 days | Evaluated the inhibitory effect of AMFL on primary and distant tumors, showing that AMFL+NIR treatment significantly suppressed primary tumor growth and controlled distant tumor growth, improving survival rates. | PMC11887044 |
C57BL/6 mice | MC38 colon carcinoma model and B16F10 melanoma model | Intratumoral injection | 150 μg | Three doses | Evaluate the antitumor effect of MSA-2-Pt in MC38 and B16F10 tumor models. The results showed that MSA-2-Pt significantly reduced tumor growth and increased survival, with 7/9 mice tumor-free in the MC38 model and 2/10 mice tumor-free in the B16F10 model. | PMC10795137 |
BALB/c mice | 4T1 breast cancer model | Intravenous injection | 2.4 mg/kg | Every 2 days for a total of 3 times | To evaluate the antitumor effect and immune activation of MSA-2 in vivo, results showed that MN NPs significantly inhibited tumor growth and promoted DC maturation and T-cell infiltration. | PMC11223770 |
FVB mice | EGFR-mutant lung cancer model | Intraperitoneal injection | 20 mg/kg | Every three days | Evaluate the effect of MSA-2 combined with osimertinib | PMC9933873 |
C57BL/6 mice | B16F10 tumor model | Orthotopic implantation | 22.5 mg/kg | Single implantation, observed for 48 hours | To evaluate the antitumor immune response of MSA-2 in vivo, results showed that MSA-2 significantly increased intratumor levels of IFNβ and IFNγ, and promoted DC maturation and T cell infiltration. | PMC11828882 |
C57BL/6 mice | Subcutaneous MC38 colorectal tumor model | Intravenous injection | 35 mg/kg | Administered on days 0, 4, and 8, total of 3 doses | To evaluate the antitumor efficacy of SAProsomes, results showed SAProsome-3 significantly inhibited tumor growth and induced 100% complete response rate. | PMC10390568 |
Mice | Subcutaneous LLC tumor model | Oral | 40 mg/kg MSA-2 orally, 5 mg/kg anti-PD-1 antibody i.p. | Administered on day 4, 8, 12 and 16 | To evaluate the anti-tumor efficacy of MSA-2 combined with anti-PD-1 therapy, results showed the combination significantly inhibited tumor growth and improved survival, which was dependent on CH25H expression | PMC9636202 |
Mice | B16, EMT-6, CT26, and H22 models | Oral | 50 mg/kg | Single dose | To evaluate the antitumor activity of MSA-2 combined with YM101, results showed the combination therapy significantly inhibited tumor growth and prolonged mouse survival. | PMC9548169 |
Mice | U14 and TC-1 cervical cancer models | Oral | 50 mg/kg | Single dose | To evaluate the inhibitory effect of MSA-2 alone or in combination with anti-PD-1 on the growth of subcutaneous cervical tumors. Results showed that MSA-2 significantly suppressed tumor growth and had a better effect when combined with anti-PD-1. | PMC10972971 |
Mice | B16F10 melanoma model | Intratumoral injection | 500 µg/dose | Administered on days 1, 4, and 7 | Evaluate the in vivo antitumor effect of DW18343, results showed DW18343 significantly inhibited tumor growth. | PMC11661907 |
C57BL/6 mice | Pan02 pancreatic cancer model | Intravenous injection | every 2 days for 16 days | Every 2 days for 16 days | Evaluate the in vivo antitumor activity of MSA-2 and cisplatin conjugates, showing significant tumor growth inhibition and enhanced immune response. | PMC10852989 |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() | 1mg | 5mg | 10mg |
1 mM 5 mM 10 mM | 3.40mL 0.68mL 0.34mL | 16.99mL 3.40mL 1.70mL | 33.98mL 6.80mL 3.40mL |
Tags: MSA-2 | MSA2 | MSA 2 | STING | Stimulator of Interferon Genes | TMEM173 | MITA | interferon-β | TNF-α | STING agonist | anti-PD-1 synergy | interferon-β secretion | STING WT | STING HAQ | 129425-81-6
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL